← Back to Guidelines

2013 AHA/ACC/TOS Obesity Management Guidelines

Clinical Quick Reference — Assessment & Treatment of Overweight and Obesity in Adults

Published: Journal of the American College of Cardiology (2014)
Societies: American College of Cardiology / American Heart Association / The Obesity Society
DOI: 10.1016/j.jacc.2013.11.004
View Full Guideline PDF

BMI Classification & Thresholds

Body mass index (BMI = weight in kg / [height in meters]²) is the standard screening tool for overweight and obesity. Measured annually in all patients; more frequently if weight gain is detected.

Category BMI (kg/m²) Clinical Action COR
Underweight <18.5 Counsel to avoid weight loss; address underlying causes 1
Normal weight 18.5–24.9 Counsel to avoid weight gain; promote healthy lifestyle 1
Overweight 25.0–29.9 Assess CVD risk factors; provide weight loss counseling if risk present 1
Obese (Class I) 30.0–34.9 Assess CVD risk; recommend weight loss intervention 1
Obese (Class II) 35.0–39.9 Weight loss strongly recommended; consider pharmacotherapy or surgery 1
Obese (Class III/Extreme) ≥40.0 Intensive weight loss intervention; strong candidate for bariatric surgery 1

Waist Circumference Thresholds

In patients with BMI 25.0–34.9 kg/m², waist circumference provides additional CVD risk stratification. Cutoffs indicate increased cardiometabolic risk:

Sex Increased Risk Substantially Increased Risk
Men >94 cm (>37 in) >102 cm (>40 in)
Women >80 cm (>31.5 in) >88 cm (>35 in)

Cardiovascular Risk Assessment

At each encounter, stratify patients by CVD risk status to guide intervention intensity. Assess presence of diabetes, hypertension, dyslipidemia, and other CVD risk factors.

Risk Category Clinical Characteristics Intervention Recommendation
Normal weight, no risk factors BMI <25.0; no HTN, DM, dyslipidemia, CVD Counsel on maintaining weight and healthy lifestyle 1
Overweight, no risk factors BMI 25.0–29.9; no CVD risk factors Advise to avoid weight gain; promote physical activity 1
Overweight/obese with risk factors BMI 25.0–29.9 with ≥1 risk factor OR BMI ≥30 Weight loss intervention (lifestyle ± pharmacotherapy ± bariatric surgery) 1
Established CVD or high-risk diabetes BMI ≥25 with history of MI, stroke, HF, or Type 2 DM with complications Intensive weight loss intervention; strong candidate for bariatric surgery if BMI ≥35 1
Key Pearl: Greater BMI and waist circumference are independently associated with increased CVD risk, all-cause mortality, incident type 2 diabetes, and incidence of hypertension. The relationship is continuous — no clear threshold effect.

Weight Loss Goals & Benefits

Weight loss of 5–10% of initial body weight is a realistic and clinically meaningful target for reducing CVD risk factors.

Weight Loss Level Expected Cardiometabolic Benefits Evidence
3–5% loss Modest improvements in triglycerides, LDL-C, insulin; modest reductions in BP 1 High
5–10% loss (initial goal) Clinically meaningful reduction in triglycerides, fasting glucose, hemoglobin A1c, BP; improved HDL-C; reduced need for medications 1 High
>10% loss Greater reductions in BP, fasting glucose, A1c, triglycerides; greater HDL-C increase; risk reduction for type 2 diabetes incidence 1 High

DO: Set Realistic Weight Loss Targets

  • Establish initial goal of 5–10% loss of baseline weight achieved within 6 months
  • For meaningful CVD benefit, sustain loss for ≥2 years
  • Emphasize that partial weight loss (3–5%) still provides health benefits
  • Individualize goals based on comorbidities and patient preferences

Comprehensive Lifestyle Intervention

Comprehensive lifestyle intervention is the foundation of weight loss treatment. All patients should be offered or referred for high-intensity lifestyle intervention (≥14 sessions over 6 months).

Core Components

Component Recommendation Details
Dietary intake Caloric deficit of 500–750 kcal/day 1 Typical intake: 1,200–1,500 kcal/day women; 1,500–1,800 kcal/day men
Physical activity ≥150 min/week moderate-intensity aerobic 1 Brisk walking; ≥30 min/day, ≥5 days/week preferred
Behavior therapy Structured behavior change program 1 Self-monitoring of weight; stimulus control; problem-solving
Delivery intensity High-intensity: ≥14 sessions over 6 months 1 Individual or group; trained interventionist; on-site preferred

Intervention Delivery Modes

Mode Expected 6-Month Weight Loss Recommendation
High-intensity in-person (≥14 sessions/6 mo) 8 kg average First-line for motivated patients 1
Telephone or electronic delivery 4–8 kg (less than in-person) Alternative when in-person unavailable 2a
Commercial programs 4.8–6.6 kg at 6–12 months Affordable options; outcomes inferior to high-intensity 2b
Low-intensity (<1–2 sessions/month) 2–4 kg Insufficient for meaningful weight loss 2b
Evidence Note: After 6 months of intensive intervention, most patients plateau. Continued intervention contact (≥1 contact/month for ≥2 years) is associated with better weight maintenance outcomes.

Dietary Strategies for Weight Loss

A variety of dietary approaches can achieve weight loss. All evidence-based diets require caloric deficit; diet choice should be individualized to patient preferences and comorbidities.

Diet Type Macronutrient Target Expected Weight Loss Evidence
Lower-fat diet 20–30% fat; higher carbohydrate 5–10% at 6–12 months 1 High
Higher-protein diet 25–30% protein (cf. typical 15%) Comparable loss; greater lipid reduction 1 High
Low-carbohydrate diet <30 g/day (induction); <40% typical Comparable weight loss over 6–12 months 2b Low
Mediterranean-style Plant foods, fish, healthy fats Weight loss with cardiovascular benefits 2b Low
Very-low-calorie (<800 kcal/d) Meal replacement; medical supervision 14–21 kg in 11–14 weeks 1 High
Key Recommendation: Counsel overweight/obese patients to achieve caloric deficit of 500–750 kcal/day. Choice of specific diet should be individualized. Any diet achieving caloric deficit is effective for weight loss.

Physical Activity Recommendations

Regular physical activity supports weight loss, weight maintenance, and reduces CVD risk. Activity should be prescribed as part of comprehensive lifestyle intervention.

Activity Level Prescription Expected Outcome COR
Moderate-intensity aerobic ≥150 min/week (brisk walking 3–4 mph) Supports weight loss; reduces CVD risk 1
Higher-intensity exercise 200–300 min/week moderate OR 150 min vigorous Greater CVD risk reduction & weight maintenance 1
Resistance training 2 sessions/week; part of comprehensive program Preserves lean muscle; enhances aerobic benefit 2a
Pitfall: Physical activity alone (without caloric restriction) typically produces modest weight loss (<3 kg). Activity is essential for maintenance and CVD benefit, but must combine with dietary intervention for substantial loss.

Pharmacotherapy for Weight Loss

Consider adding FDA-approved weight loss medications as adjunct to lifestyle intervention for patients with BMI ≥30 kg/m² (or ≥27 with comorbidities) who have not achieved sufficient loss with lifestyle alone.

Medication Mechanism Expected Loss Key Considerations
Orlistat Pancreatic lipase inhibitor; reduces fat absorption 2–3 kg additional at 1 year vs. placebo OTC available; GI side effects; fat-restricted diet required
Phentermine Sympathomimetic; appetite suppressant 3–5 kg loss; not sustained beyond 12 weeks monotherapy Approved <12 weeks; monitor BP & HR; contraindicated with CVD

2a Consider pharmacotherapy as adjunct to lifestyle intervention for patients motivated to lose weight with BMI ≥30 or ≥27 with comorbidities who have not achieved sufficient loss with lifestyle alone.

Important: Pharmacotherapy helps patients achieve lower-calorie intake more consistently and sustain weight loss. Medications work best as reinforcement of lifestyle change. Discontinue if <5% weight loss after 12 weeks at maximal dose.

Bariatric Surgery for Obesity

Bariatric surgery is recommended for motivated patients with obesity-related comorbidities who have insufficient response to behavioral treatment and pharmacotherapy.

Eligibility & Indications

Category BMI Threshold Additional Criteria COR
Extreme obesity BMI ≥40 kg/m² Motivated; no contraindications; able to tolerate anesthesia 1
With comorbidities BMI ≥35 kg/m² with ≥1 obesity-related comorbidity Failed behavioral/pharmacotherapy; motivated; medical risk acceptable 1
BMI <35 <35 kg/m² Insufficient evidence for routine recommendation 3

Efficacy & Outcomes

Weight Loss

20–35% of initial body weight at 2–3 years; sustained with proper management

Type 2 Diabetes

Remission or improved glycemic control in majority; lower incidence of new-onset diabetes vs. nonsurgical management

Hypertension

Reduction in prevalence and medication need; more frequent improvement after gastric bypass than LAGB

Mortality

Total mortality reduced at mean 11-year follow-up vs. nonsurgical controls; predominantly in BMI >40

Complications

Procedure Operative Complications Long-Term (>30 days) Frequency (experienced surgeon)
LAGB Rare (<1%); DVT/PE, port complications Band migration/erosion (3–4%); revision 2–34% at 2–10 yr Low with experienced surgeon
Gastric Bypass 4–5% (leak, DVT/PE); mortality 0.2% Vitamin deficiency (D, B12, iron); complications 6–18% Lower with laparoscopic approach
Sleeve Gastrectomy Insufficient evidence on perioperative safety Limited long-term data available Data insufficient; recommend study enrollment

DO: Offer Referral for Bariatric Surgery Consultation

  • Refer adults with BMI ≥40 kg/m² or ≥35 kg/m² with obesity-related comorbidities who are motivated
  • Decision requires multidisciplinary evaluation (surgeon, anesthesiologist, mental health assessment if indicated)
  • Discuss realistic weight loss expectations, nutritional supplementation needs, and potential complications
  • Ensure patient understanding that surgery is adjunct to lifestyle intervention, not replacement

Weight Loss Maintenance

Obesity is a chronic condition. After achieving weight loss, continued intervention is necessary to prevent weight regain. Long-term success requires ongoing contact (≥1 contact/month for ≥2 years).

Maintenance Strategies

Strategy Frequency/Intensity Expected Outcome
Continued intervention contact Monthly or more frequent; in-person or telephone 35% of initial loss maintained at ≥2.5 years vs. minimal intervention
Frequent self-weighing ≥1 time weekly; more frequent acceptable Associated with better long-term maintenance; early regain detection
High physical activity >200 min/week moderate intensity Essential component of successful long-term weight maintenance
Reduced-calorie diet Continue caloric restriction; energy balance on achieved weight Prevent gradual weight regain; maintain CVD risk reduction
Maximum weight loss is achieved at 6 months; plateau and gradual regain observed over time. With medication-assisted loss, weight regain may occur even with continued medication. Flexibility and willingness to try different approaches are recommended.

Treatment Algorithm: Chronic Disease Management Model

This integrated algorithm guides clinicians through patient assessment, risk stratification, and treatment decisions for overweight and obesity.

Obesity Management Workflow

Step 1: Patient Encounter
Initiate assessment of weight status. Discuss obesity prevention and management. 1
Step 2: Measure & Calculate BMI
Measure weight and height without clothing; calculate BMI (kg/m²). Document in medical record. Measure annually at minimum. 1
Step 3: Determine BMI Category
Classify as underweight (<18.5), normal (18.5–24.9), overweight (25.0–29.9), obese class I (30.0–34.9), obese class II (35.0–39.9), or extreme obesity (≥40.0). 1
Step 4: Assess CVD Risk & Comorbidities
Evaluate presence of diabetes, hypertension, dyslipidemia, elevated waist circumference, and other risk factors. 1
Step 5a: Normal BMI (<25.0) OR Overweight Without Risk
Counsel to avoid weight gain. Promote healthy lifestyle. No weight loss intervention indicated. 1
Step 5b: Overweight/Obese WITH Risk Factors OR BMI ≥30
Assess readiness for lifestyle change. Provide counseling on weight loss benefits. 1
Step 6: Assess Readiness for Lifestyle Change
Determine if patient is prepared and able to undertake measures necessary for weight loss. Discuss barriers. 1
Step 7: Patient Ready for Weight Loss Intervention
Set goal of 5–10% baseline weight loss. Recommend comprehensive lifestyle intervention (diet, physical activity, behavior therapy). 1
Step 7b: Patient Not Ready
Revisit at future visits. Address obstacles (competing priorities, comorbidities, medications). 1
Step 8: Offer Comprehensive Lifestyle Intervention
Refer for high-intensity lifestyle program (≥14 sessions over 6 months). Components: reduced-calorie diet (500–750 kcal/d deficit), ≥150 min/week physical activity, behavioral strategies. 1
Step 9: Assess Weight Loss Response After 6 Months
If >5% loss: Continue intervention, transition to maintenance. 1
If <5% loss: Consider intensification or adjunctive therapy.
Step 10: Weight Loss <5% → Consider Adjunctive Therapy
Options: (a) Intensified behavioral therapy, (b) Add pharmacotherapy (BMI ≥30 or ≥27 with comorbidities), (c) Bariatric surgery evaluation (BMI ≥35 with comorbidities or ≥40). 2a
Step 11: Weight Loss ≥5% Achieved
Evaluate health outcome improvements (BP, glucose, lipids). Continue current intervention. Consider bariatric surgery if BMI ≥40 or ≥35 with significant comorbidities. 1
Step 12: Weight Loss Maintenance Program
Continue follow-up ≥monthly. Monitor weight ≥annually. Maintain reduced-calorie diet and activity (>200 min/week). Self-weigh frequently. Reinforce behavior change. 1
Step 13: Ongoing Medical Management
Actively manage CVD risk factors and obesity-related comorbidities regardless of weight loss success. Reassess and adjust medications as weight loss and risk factors change. 1

Special Populations & Comorbidities

Type 2 Diabetes

Weight loss of 2.5–5.5 kg at ≥2 years: Reduces type 2 diabetes incidence by 30–60% in overweight/obese individuals at risk. 1

Weight loss of 5–10%: Improves fasting glucose, A1c (mean reduction 0.6%), and reduces medication need. 1

Monitoring: Reassess medication requirements (insulin, sulfonylureas) as weight loss progresses to prevent hypoglycemia. 1

Hypertension

Weight loss of 3–5 kg: Approximately 3 mmHg reduction in systolic and 2 mmHg in diastolic BP. 1

Greater weight loss: More substantial BP reduction. 1

Medication adjustment: Monitor BP frequently. Reduce antihypertensive doses as weight loss progresses and BP improves.

Dyslipidemia

Weight loss outcomes: Lower-fat diets produce greater LDL-C reduction; higher-protein diets produce comparable overall benefit with less HDL-C increase. 1

Triglycerides: Weight loss of ≥3 kg produces ≥15 mg/dL reduction in triglycerides. 1

Related Calculators

Use these tools to complement obesity management and guide CV risk assessment:

Ideal Body Weight (IBW)

Calculate target weight range for reference.

PREVENT-ASCVD Risk Calculator

Estimate 10-year and 30-year ASCVD risk to guide intensity of CV risk factor management.

Pooled Cohort Equations (PCE)

Calculate 10-year ASCVD risk for primary prevention.

Framingham Risk Score

Estimate 10-year coronary heart disease risk.